Lannett Company, Inc. (NYSE MKT: LCI) today announced that it expects to
report fiscal 2013 third quarter net sales of approximately $39 million
and diluted earnings per share between $0.12 and $0.14. For the prior
year third quarter, net sales were $30.7 million and diluted earnings
per share were $0.06. The company said the improved performance was
driven by strong sales of existing and new products, as well as solid
gross margin due to favorable product mix and enhanced manufacturing
Lannett will report full financial results for its fiscal 2013 third
quarter Wednesday, May 8, 2013 after the market closes and will host a
conference call that same afternoon at 4:30 p.m. Eastern (1:30 p.m.
Pacific) to review the company's performance and answer questions.
The conference call will be available to interested parties by dialing
877-261-8992 from the U.S. or Canada, or 847-619-6548 from international
locations, passcode 34792521. The call will also be available through a
live, listen-only audio broadcast via the Internet at www.lannett.com.
Listeners are encouraged to visit the website at least 15 minutes prior
to the start of the scheduled presentation to register, download and
install any necessary audio software. A playback of the call will be
archived and accessible on the same website for at least three months.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages,
markets and distributes generic pharmaceutical products for a wide range
of medical indications. For more information, visit the company's
website at www.lannett.com.
This news release contains certain statements of a forward-looking
nature relating to future events or future business performance. Any
such statements, including, but not limited to, the reporting of its
preliminary financial results, whether expressed or implied, are subject
to risks and uncertainties which can cause actual results to differ
materially from those currently anticipated due to a number of factors
which include, but are not limited to, the difficulty in predicting the
timing or outcome of FDA or other regulatory approvals or actions, the
ability to successfully commercialize products upon approval, Lannett's
estimated or anticipated future financial results, future inventory
levels, future competition or pricing, future levels of operating
expenses, product development efforts or performance, and other risk
factors discussed in the company's Form 10-K and other documents filed
with the Securities and Exchange Commission from time to time. These
forward-looking statements represent the company's judgment as of the
date of this news release. The company disclaims any intent or
obligation to update these forward-looking statements.
Roger Pondel, 310-279-5980